Akari Net Tangible Assets vs Net Debt Analysis

AKTX Stock

USD 1.01 0.02 1.94%

Akari Therapeutics financial indicator trend analysis is way more than just evaluating Akari Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akari Therapeutics PLC is a good investment. Please check the relationship between Akari Therapeutics Net Tangible Assets and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Net Tangible Assets vs Net Debt

Net Tangible Assets vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akari Therapeutics PLC Net Tangible Assets account and Net Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Akari Therapeutics' Net Tangible Assets and Net Debt is -0.95. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Akari Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Akari Therapeutics' Net Tangible Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Akari Therapeutics PLC are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Net Tangible Assets i.e., Akari Therapeutics' Net Tangible Assets and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.95

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Akari Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Issuance Of Capital Stock is likely to rise to about 15.1 M in 2025, whereas Selling General Administrative is likely to drop slightly above 7.7 M in 2025.

Akari Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Debt	Cash	Common Stock Total Equity	Short Long Term Debt Total	Non Current Assets Total	Property Plant And Equipment Gross	Short Term Debt	Current Deferred Revenue	Short Long Term Debt	Intangible Assets	Other Liab
Total Assets		0.73	0.92	0.9	-0.3	0.69	0.68	0.24	0.1	0.43	0.2	0.45	0.87	0.67	0.41	-0.64	0.68	0.28	0.6	0.55	0.32	0.6	-0.48	0.63	0.55	0.63
Other Current Liab	0.73		0.72	0.76	-0.21	0.15	0.85	0.24	0.14	-0.08	0.32	0.29	0.54	0.84	0.46	-0.84	0.85	0.45	0.57	0.0	0.13	0.57	-0.53	0.57	0.0	0.16
Total Current Liabilities	0.92	0.72		0.69	-0.51	0.79	0.5	0.1	0.04	0.58	0.09	0.63	0.97	0.47	0.25	-0.45	0.5	0.1	0.67	0.68	0.51	0.67	-0.45	0.68	0.68	0.62
Total Stockholder Equity	0.9	0.76	0.69		-0.04	0.34	0.88	0.36	0.17	0.07	0.33	0.17	0.57	0.89	0.5	-0.85	0.87	0.46	0.47	0.17	0.06	0.47	-0.47	0.49	0.16	0.42
Retained Earnings	-0.3	-0.21	-0.51	-0.04		-0.56	0.15	-0.25	0.03	-0.64	-0.32	-0.97	-0.55	0.13	-0.03	-0.17	0.14	0.09	-0.8	-0.55	-0.88	-0.8	0.65	-0.82	-0.55	-0.23
Accounts Payable	0.69	0.15	0.79	0.34	-0.56		-0.03	-0.02	-0.08	0.89	-0.09	0.67	0.91	-0.05	0.03	0.08	-0.03	-0.18	0.5	0.97	0.6	0.5	-0.23	0.52	0.97	0.73
Cash And Short Term Investments	0.68	0.85	0.5	0.88	0.15	-0.03		0.24	0.21	-0.28	0.28	-0.05	0.3	0.99	0.43	-0.99	0.99	0.47	0.31	-0.22	-0.11	0.31	-0.38	0.32	-0.22	0.12
Net Receivables	0.24	0.24	0.1	0.36	-0.25	-0.02	0.24		0.49	-0.11	0.65	0.24	0.04	0.33	0.67	-0.19	0.19	0.66	0.56	-0.05	0.02	0.56	-0.53	0.56	-0.05	0.17
Common Stock Shares Outstanding	0.1	0.14	0.04	0.17	0.03	-0.08	0.21	0.49		-0.17	0.03	-0.04	-0.01	0.2	0.36	-0.23	0.23	0.37	0.15	-0.09	-0.09	0.15	-0.16	0.15	-0.1	-0.17
Non Current Liabilities Total	0.43	-0.08	0.58	0.07	-0.64	0.89	-0.28	-0.11	-0.17		0.0	0.74	0.73	-0.3	-0.18	0.32	-0.28	-0.36	0.43	0.91	0.71	0.43	-0.19	0.45	0.91	0.59
Other Current Assets	0.2	0.32	0.09	0.33	-0.32	-0.09	0.28	0.65	0.03	0.0		0.32	0.0	0.37	0.42	-0.26	0.25	0.44	0.56	-0.16	0.13	0.56	-0.55	0.56	-0.16	-0.01
Other Stockholder Equity	0.45	0.29	0.63	0.17	-0.97	0.67	-0.05	0.24	-0.04	0.74	0.32		0.67	-0.04	0.06	0.08	-0.05	-0.08	0.84	0.63	0.89	0.84	-0.63	0.86	0.63	0.33
Total Liab	0.87	0.54	0.97	0.57	-0.55	0.91	0.3	0.04	-0.01	0.73	0.0	0.67		0.27	0.18	-0.25	0.3	0.0	0.61	0.84	0.55	0.61	-0.37	0.63	0.84	0.7
Total Current Assets	0.67	0.84	0.47	0.89	0.13	-0.05	0.99	0.33	0.2	-0.3	0.37	-0.04	0.27		0.51	-0.98	0.98	0.55	0.36	-0.25	-0.13	0.36	-0.43	0.37	-0.25	0.09
Common Stock	0.41	0.46	0.25	0.5	-0.03	0.03	0.43	0.67	0.36	-0.18	0.42	0.06	0.18	0.51		-0.42	0.42	0.98	0.47	-0.04	-0.33	0.47	-0.46	0.48	-0.04	0.07
Net Debt	-0.64	-0.84	-0.45	-0.85	-0.17	0.08	-0.99	-0.19	-0.23	0.32	-0.26	0.08	-0.25	-0.98	-0.42		-1.0	-0.46	-0.28	0.27	0.14	-0.28	0.36	-0.29	0.28	0.0
Cash	0.68	0.85	0.5	0.87	0.14	-0.03	0.99	0.19	0.23	-0.28	0.25	-0.05	0.3	0.98	0.42	-1.0		0.45	0.3	-0.22	-0.11	0.3	-0.37	0.31	-0.22	0.04
Common Stock Total Equity	0.28	0.45	0.1	0.46	0.09	-0.18	0.47	0.66	0.37	-0.36	0.44	-0.08	0.0	0.55	0.98	-0.46	0.45		0.37	-0.24	-0.45	0.37	-0.4	0.37	-0.25	-0.08
Short Long Term Debt Total	0.6	0.57	0.67	0.47	-0.8	0.5	0.31	0.56	0.15	0.43	0.56	0.84	0.61	0.36	0.47	-0.28	0.3	0.37		0.38	0.59	1.0	-0.76	0.99	0.38	0.28
Non Current Assets Total	0.55	0.0	0.68	0.17	-0.55	0.97	-0.22	-0.05	-0.09	0.91	-0.16	0.63	0.84	-0.25	-0.04	0.27	-0.22	-0.24	0.38		0.58	0.38	-0.15	0.41	1.0	0.74
Property Plant And Equipment Gross	0.32	0.13	0.51	0.06	-0.88	0.6	-0.11	0.02	-0.09	0.71	0.13	0.89	0.55	-0.13	-0.33	0.14	-0.11	-0.45	0.59	0.58		0.59	-0.51	0.63	0.58	0.32
Short Term Debt	0.6	0.57	0.67	0.47	-0.8	0.5	0.31	0.56	0.15	0.43	0.56	0.84	0.61	0.36	0.47	-0.28	0.3	0.37	1.0	0.38	0.59		-0.76	0.99	0.38	0.28
Current Deferred Revenue	-0.48	-0.53	-0.45	-0.47	0.65	-0.23	-0.38	-0.53	-0.16	-0.19	-0.55	-0.63	-0.37	-0.43	-0.46	0.36	-0.37	-0.4	-0.76	-0.15	-0.51	-0.76		-0.78	-0.15	-0.1
Short Long Term Debt	0.63	0.57	0.68	0.49	-0.82	0.52	0.32	0.56	0.15	0.45	0.56	0.86	0.63	0.37	0.48	-0.29	0.31	0.37	0.99	0.41	0.63	0.99	-0.78		0.41	0.3
Intangible Assets	0.55	0.0	0.68	0.16	-0.55	0.97	-0.22	-0.05	-0.1	0.91	-0.16	0.63	0.84	-0.25	-0.04	0.28	-0.22	-0.25	0.38	1.0	0.58	0.38	-0.15	0.41		0.73
Other Liab	0.63	0.16	0.62	0.42	-0.23	0.73	0.12	0.17	-0.17	0.59	-0.01	0.33	0.7	0.09	0.07	0.0	0.04	-0.08	0.28	0.74	0.32	0.28	-0.1	0.3	0.73

Click cells to compare fundamentals

Akari Therapeutics Account Relationship Matchups

Akari Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	17.6M	11.6M	13.8M	4.4M	50.6M	53.1M
Other Current Liab	1.8M	4.3M	11.1M	2.9M	4.2M	5.2M
Total Current Liabilities	5.2M	6.1M	12.0M	4.6M	19.9M	20.9M
Total Stockholder Equity	12.4M	5.6M	1.8M	(229K)	22.2M	12.1M
Retained Earnings	(156.6M)	(199.7M)	(217.5M)	(227.5M)	(247.3M)	(234.9M)
Accounts Payable	3.4M	1.8M	947K	1.7M	12.4M	13.0M
Cash And Short Term Investments	14.1M	9.4M	13.2M	3.8M	2.6M	2.5M
Common Stock Shares Outstanding	1.6K	2.1K	3.1K	4.9K	11.9K	11.3K
Liabilities And Stockholders Equity	17.6M	11.6M	13.8M	4.4M	50.6M	53.1M
Non Current Liabilities Total	3.4M	4.3M	946.7K	0.0	8.4M	8.8M
Other Current Assets	521.9K	2.3M	564.8K	496K	353K	335.4K
Other Stockholder Equity	191.9M	205.3M	219.3M	174.8M	264.9M	278.1M
Total Liab	5.2M	6.1M	12.0M	4.6M	28.3M	29.7M
Total Current Assets	17.6M	11.6M	13.8M	4.3M	3.0M	2.8M
Accumulated Other Comprehensive Income	(10.9M)	(541.0K)	(770.8K)	51.2M	(738K)	(701.1K)
Common Stock	385K	476.0K	744.5K	1.3M	5.3M	9.2M
Net Debt	(14.1M)	(9.4M)	(13.2M)	(3.8M)	661K	694.1K
Cash	14.1M	9.4M	13.2M	3.8M	2.6M	2.5M
Non Current Assets Total	27K	22.9K	16.9K	14K	47.6M	50.0M
Property Plant And Equipment Gross	20.4K	5.0K	172K	164.9K	197.8K	207.7K
Intangible Assets	27K	22.9K	16.9K	14K	39.2M	41.1M
Net Tangible Assets	3.1M	(1.8M)	9.4M	5.5M	5.0M	4.7M
Net Invested Capital	9.4M	5.6M	1.8M	(229K)	25.5M	26.8M
Net Working Capital	9.4M	5.5M	1.8M	(243K)	(17.0M)	(16.1M)
Capital Stock	384.7K	476.0K	744.5K	1.3M	5.3M	7.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Akari Net Tangible Assets vs Net Debt Analysis

Net Tangible Assets vs Net Debt

Net Tangible Assets vs Net Debt Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Net Debt

Akari Therapeutics fundamental ratios Correlations

Akari Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akari Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Akari Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Intangible Assets	+ 1.0	Non Current Assets Total
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash	+ 0.99	Cash And Short Term Investments
Short Long Term Debt	+ 0.99	Short Long Term Debt Total
Short Long Term Debt	+ 0.99	Short Term Debt

Cash	- 1.0	Net Debt
Net Debt	- 0.99	Cash And Short Term Investments
Net Debt	- 0.98	Total Current Assets
Other Stockholder Equity	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.88	Retained Earnings
Net Debt	- 0.85	Total Stockholder Equity